With the NHS under such exceptional pressure during the coronavirus crisis, it’s easy to overlook the fact that the UK’s Brexit transition period ends on December 31. Mark Dayan takes a closer look at how these two challenges for the health service might collide, and says there is a case to err on the side of caution.

Confidence is at rock-bottom in the UK's ability to attract and retain the best scientific and engineering talent from Europe.

The BMA has published a series of briefings, which outline our policy positions on a range of key issues relating to the impact of Brexit on the UK healthcare system.

RESEARCH experts and charities working with people with serious and often terminal illnesses have said that delays to research and clinical trials from Brexit could mean the difference between "life or death" for patients.

Brexit has forced the University of Cambridge – one of the world’s leading third-level institutions – to establish a unit in Ireland so that it can continue to engage in clinical trials research across the EU, the Irish Independent has learned.

The coronavirus should remind us of just why international cooperation is so important in reducing the threat of infectious disease.

Brexit could have major implications for health and social care in England. Here we look at some of the latest developments that could have an impact.

The shareholding in the Irish firm is held on behalf of the chancellor, masters and scholars of the University of Cambridge.

Head of Commons health committee also raises alarm over UK missing out on benefits of new clinical trials.

The UK left the EU on January 31, 2020, and this began the complex process of de-coupling the UK regulatory regime from that of the EU. This has not been straightforward, particularly where goods move into and out of Northern Ireland (NI), where the EU rules continue to apply, from Great Britain (England, Wales, and Scotland (GB)), where they do not.

Ministers will relax rules around clinical trials and streamline the approval of new medicines in a bid to maintain Britain’s competitiveness following Brexit.

UK researchers fear being blocked from EU-wide testing of treatments for diseases including rare childhood cancers.

San Francisco-based clinical-stage life science company Recardio is halting clinical trials in the U.K. of a new heart drug due to concerns about Brexit and how new drugs will be approved.

As obvious as it is to see the decline in the number of clinical trials in the UK, the reasons behind this trend are as complicated to ascertain. Fiona Maini, Principal - Global Compliance and Strategy at Medidata Solutions, thinks the issue is multifaced with Brexit playing a part in this.

The government has set out a plan to overhaul EU laws copied over after Brexit - a move it says will cut unnecessary "red tape" for businesses.